AustralieFrV1, PubMed, Corpus, bibRecord, 002741

How individual participant data meta-analyses have influenced trial design, conduct, and analysis.

Identifieur interne : 002741 ( PubMed/Corpus ); précédent : 002740; suivant : 002742

How individual participant data meta-analyses have influenced trial design, conduct, and analysis.

Auteurs : Jayne F. Tierney ; Jean-Pierre Pignon ; Francois Gueffyier ; Mike Clarke ; Lisa Askie ; Claire L. Vale ; Sarah Burdett

Source :

Journal of clinical epidemiology [ 1878-5921 ] ; 2015.

RBID : pubmed:26186982

English descriptors

KwdEn :
- Clinical Trials as Topic (methods), Humans, Meta-Analysis as Topic, Research Design, Research Subjects, Statistics as Topic.
MESH :
- methods : Clinical Trials as Topic.
- Humans, Meta-Analysis as Topic, Research Design, Research Subjects, Statistics as Topic.

Abstract

To demonstrate how individual participant data (IPD) meta-analyses have impacted directly on the design and conduct of trials and highlight other advantages IPD might offer.

DOI: 10.1016/j.jclinepi.2015.05.024
PubMed: 26186982

Links to Exploration step

pubmed:26186982

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">How individual participant data meta-analyses have influenced trial design, conduct, and analysis.</title>
<author><name sortKey="Tierney, Jayne F" sort="Tierney, Jayne F" uniqKey="Tierney J" first="Jayne F" last="Tierney">Jayne F. Tierney</name>
<affiliation><nlm:affiliation>MRC Clinical Trials Unit at UCL, Aviation House, 125 Kingsway, London WC2B 6NH, UK. Electronic address: jayne.tierney@ucl.ac.uk.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Pignon, Jean Pierre" sort="Pignon, Jean Pierre" uniqKey="Pignon J" first="Jean-Pierre" last="Pignon">Jean-Pierre Pignon</name>
<affiliation><nlm:affiliation>LNCC plateforme de méta-analyse en oncologie, Service de Biostatistique et d'Epidemiologie, Gustave-Roussy, Villejuif, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Gueffyier, Francois" sort="Gueffyier, Francois" uniqKey="Gueffyier F" first="Francois" last="Gueffyier">Francois Gueffyier</name>
<affiliation><nlm:affiliation>Université Claude Bernard Lyon 1/Université de Lyon, 69365 Lyon Cedex 07, Lyon, France; Service de Pharmacologie Clinique, Hospices Civils de Lyon, Bron cedex, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Clarke, Mike" sort="Clarke, Mike" uniqKey="Clarke M" first="Mike" last="Clarke">Mike Clarke</name>
<affiliation><nlm:affiliation>All-Ireland Hub for Trials Methodology Research, Queen's University Belfast, University Road, Belfast BT7 1NN, Northern Ireland, UK.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Askie, Lisa" sort="Askie, Lisa" uniqKey="Askie L" first="Lisa" last="Askie">Lisa Askie</name>
<affiliation><nlm:affiliation>NHMRC Clinical Trials Centre, ABN 15 211 513 464, Locked Bag 77, Camperdown, NSW 1450 Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Vale, Claire L" sort="Vale, Claire L" uniqKey="Vale C" first="Claire L" last="Vale">Claire L. Vale</name>
<affiliation><nlm:affiliation>MRC Clinical Trials Unit at UCL, Aviation House, 125 Kingsway, London WC2B 6NH, UK.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Burdett, Sarah" sort="Burdett, Sarah" uniqKey="Burdett S" first="Sarah" last="Burdett">Sarah Burdett</name>
<affiliation><nlm:affiliation>MRC Clinical Trials Unit at UCL, Aviation House, 125 Kingsway, London WC2B 6NH, UK.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:26186982</idno>
<idno type="pmid">26186982</idno>
<idno type="doi">10.1016/j.jclinepi.2015.05.024</idno>
<idno type="wicri:Area/PubMed/Corpus">002741</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002741</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">How individual participant data meta-analyses have influenced trial design, conduct, and analysis.</title>
<author><name sortKey="Tierney, Jayne F" sort="Tierney, Jayne F" uniqKey="Tierney J" first="Jayne F" last="Tierney">Jayne F. Tierney</name>
<affiliation><nlm:affiliation>MRC Clinical Trials Unit at UCL, Aviation House, 125 Kingsway, London WC2B 6NH, UK. Electronic address: jayne.tierney@ucl.ac.uk.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Pignon, Jean Pierre" sort="Pignon, Jean Pierre" uniqKey="Pignon J" first="Jean-Pierre" last="Pignon">Jean-Pierre Pignon</name>
<affiliation><nlm:affiliation>LNCC plateforme de méta-analyse en oncologie, Service de Biostatistique et d'Epidemiologie, Gustave-Roussy, Villejuif, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Gueffyier, Francois" sort="Gueffyier, Francois" uniqKey="Gueffyier F" first="Francois" last="Gueffyier">Francois Gueffyier</name>
<affiliation><nlm:affiliation>Université Claude Bernard Lyon 1/Université de Lyon, 69365 Lyon Cedex 07, Lyon, France; Service de Pharmacologie Clinique, Hospices Civils de Lyon, Bron cedex, France.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Clarke, Mike" sort="Clarke, Mike" uniqKey="Clarke M" first="Mike" last="Clarke">Mike Clarke</name>
<affiliation><nlm:affiliation>All-Ireland Hub for Trials Methodology Research, Queen's University Belfast, University Road, Belfast BT7 1NN, Northern Ireland, UK.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Askie, Lisa" sort="Askie, Lisa" uniqKey="Askie L" first="Lisa" last="Askie">Lisa Askie</name>
<affiliation><nlm:affiliation>NHMRC Clinical Trials Centre, ABN 15 211 513 464, Locked Bag 77, Camperdown, NSW 1450 Australia.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Vale, Claire L" sort="Vale, Claire L" uniqKey="Vale C" first="Claire L" last="Vale">Claire L. Vale</name>
<affiliation><nlm:affiliation>MRC Clinical Trials Unit at UCL, Aviation House, 125 Kingsway, London WC2B 6NH, UK.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Burdett, Sarah" sort="Burdett, Sarah" uniqKey="Burdett S" first="Sarah" last="Burdett">Sarah Burdett</name>
<affiliation><nlm:affiliation>MRC Clinical Trials Unit at UCL, Aviation House, 125 Kingsway, London WC2B 6NH, UK.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of clinical epidemiology</title>
<idno type="eISSN">1878-5921</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Clinical Trials as Topic (methods)</term>
<term>Humans</term>
<term>Meta-Analysis as Topic</term>
<term>Research Design</term>
<term>Research Subjects</term>
<term>Statistics as Topic</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Clinical Trials as Topic</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
<term>Meta-Analysis as Topic</term>
<term>Research Design</term>
<term>Research Subjects</term>
<term>Statistics as Topic</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">To demonstrate how individual participant data (IPD) meta-analyses have impacted directly on the design and conduct of trials and highlight other advantages IPD might offer.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26186982</PMID>
<DateCreated><Year>2015</Year>
<Month>10</Month>
<Day>28</Day>
</DateCreated>
<DateCompleted><Year>2016</Year>
<Month>02</Month>
<Day>04</Day>
</DateCompleted>
<DateRevised><Year>2017</Year>
<Month>09</Month>
<Day>22</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-5921</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>68</Volume>
<Issue>11</Issue>
<PubDate><Year>2015</Year>
<Month>Nov</Month>
</PubDate>
</JournalIssue>
<Title>Journal of clinical epidemiology</Title>
<ISOAbbreviation>J Clin Epidemiol</ISOAbbreviation>
</Journal>
<ArticleTitle>How individual participant data meta-analyses have influenced trial design, conduct, and analysis.</ArticleTitle>
<Pagination><MedlinePgn>1325-35</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jclinepi.2015.05.024</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0895-4356(15)00268-1</ELocationID>
<Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To demonstrate how individual participant data (IPD) meta-analyses have impacted directly on the design and conduct of trials and highlight other advantages IPD might offer.</AbstractText>
<AbstractText Label="STUDY DESIGN AND SETTING" NlmCategory="METHODS">Potential examples of the impact of IPD meta-analyses on trials were identified at an international workshop, attended by individuals with experience in the conduct of IPD meta-analyses and knowledge of trials in their respective clinical areas. Experts in the field who did not attend were asked to provide any further examples. We then examined relevant trial protocols, publications, and Web sites to verify the impacts of the IPD meta-analyses. A subgroup of workshop attendees sought further examples and identified other aspects of trial design and conduct that may inform IPD meta-analyses.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">We identified 52 examples of IPD meta-analyses thought to have had a direct impact on the design or conduct of trials. After screening relevant trial protocols and publications, we identified 28 instances where IPD meta-analyses had clearly impacted on trials. They have influenced the selection of comparators and participants, sample size calculations, analysis and interpretation of subsequent trials, and the conduct and analysis of ongoing trials, sometimes in ways that would not possible with systematic reviews of aggregate data. We identified additional potential ways that IPD meta-analyses could be used to influence trials.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">IPD meta-analysis could be better used to inform the design, conduct, analysis, and interpretation of trials.</AbstractText>
<CopyrightInformation>Crown Copyright © 2015. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tierney</LastName>
<ForeName>Jayne F</ForeName>
<Initials>JF</Initials>
<AffiliationInfo><Affiliation>MRC Clinical Trials Unit at UCL, Aviation House, 125 Kingsway, London WC2B 6NH, UK. Electronic address: jayne.tierney@ucl.ac.uk.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pignon</LastName>
<ForeName>Jean-Pierre</ForeName>
<Initials>JP</Initials>
<AffiliationInfo><Affiliation>LNCC plateforme de méta-analyse en oncologie, Service de Biostatistique et d'Epidemiologie, Gustave-Roussy, Villejuif, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gueffyier</LastName>
<ForeName>Francois</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Université Claude Bernard Lyon 1/Université de Lyon, 69365 Lyon Cedex 07, Lyon, France; Service de Pharmacologie Clinique, Hospices Civils de Lyon, Bron cedex, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Clarke</LastName>
<ForeName>Mike</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>All-Ireland Hub for Trials Methodology Research, Queen's University Belfast, University Road, Belfast BT7 1NN, Northern Ireland, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Askie</LastName>
<ForeName>Lisa</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>NHMRC Clinical Trials Centre, ABN 15 211 513 464, Locked Bag 77, Camperdown, NSW 1450 Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Vale</LastName>
<ForeName>Claire L</ForeName>
<Initials>CL</Initials>
<AffiliationInfo><Affiliation>MRC Clinical Trials Unit at UCL, Aviation House, 125 Kingsway, London WC2B 6NH, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Burdett</LastName>
<ForeName>Sarah</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>MRC Clinical Trials Unit at UCL, Aviation House, 125 Kingsway, London WC2B 6NH, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><CollectiveName>Cochrane IPD Meta-analysis Methods Group</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>U20</GrantID>
<Agency>Medical Research Council</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant><GrantID>MR/K025635/1</GrantID>
<Agency>Medical Research Council</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant><GrantID>MR/L004933/1</GrantID>
<Agency>Medical Research Council</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant><GrantID>G0800792</GrantID>
<Agency>Medical Research Council</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant><GrantID>G0902303</GrantID>
<Agency>Medical Research Council</Agency>
<Country>United Kingdom</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2015</Year>
<Month>06</Month>
<Day>03</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>J Clin Epidemiol</MedlineTA>
<NlmUniqueID>8801383</NlmUniqueID>
<ISSNLinking>0895-4356</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2010 Jul 3;376(9734):20-1</RefSource>
<PMID Version="1">20609983</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 1999 Feb 6;353(9151):490-3</RefSource>
<PMID Version="1">9989737</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Epidemiol. 2011 Sep;64(9):949-67</RefSource>
<PMID Version="1">21411280</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Stat Med. 2002 Feb 15;21(3):371-87</RefSource>
<PMID Version="1">11813224</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS Med. 2015 Jul;12(7):e1001855</RefSource>
<PMID Version="1">26196287</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>JAMA. 2015 Apr 28;313(16):1657-65</RefSource>
<PMID Version="1">25919529</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2007 May 26;369(9575):1791-8</RefSource>
<PMID Version="1">17512048</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2009 May;10(5):467-74</RefSource>
<PMID Version="1">19386548</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Diabetologia. 2001 Sep;44(9):1118-20</RefSource>
<PMID Version="1">11596665</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Hypertens. 2003 Dec;21(12):2409-17</RefSource>
<PMID Version="1">14654762</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2006 Feb 1;24(4):619-25</RefSource>
<PMID Version="1">16446334</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Stat Med. 1995 Oct 15;14(19):2057-79</RefSource>
<PMID Version="1">8552887</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS Med. 2004 Nov;1(2):e35</RefSource>
<PMID Version="1">15578106</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2014 Apr 20;32(12):1256-61</RefSource>
<PMID Version="1">24638013</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Stroke. 2008 Jun;39(6):1821-6</RefSource>
<PMID Version="1">18403738</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur Urol. 2005 Aug;48(2):189-199; discussion 199-201</RefSource>
<PMID Version="1">15939530</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2012 Jun 23;379(9834):2352-63</RefSource>
<PMID Version="1">22632908</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2009 Apr;10(4):341-50</RefSource>
<PMID Version="1">19246242</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>BMC Med Res Methodol. 2013;13:50</RefSource>
<PMID Version="1">23530582</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arch Intern Med. 2009 Sep 14;169(16):1532-4</RefSource>
<PMID Version="1">19752412</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lung Cancer. 2013 Jun;80(3):350-2</RefSource>
<PMID Version="1">23453644</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 1999 Aug 12;341(7):476-84</RefSource>
<PMID Version="1">10441603</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Trials. 2005;2(3):260-4</RefSource>
<PMID Version="1">16279149</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 1998 Nov 14;352(9140):1571-6</RefSource>
<PMID Version="1">9843101</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Diabetes Care. 2000 Apr;23 Suppl 2:B65-71</RefSource>
<PMID Version="1">10860193</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>BMJ. 2012;345:e7888</RefSource>
<PMID Version="1">23169872</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Biostatistics. 2000 Mar;1(1):49-67</RefSource>
<PMID Version="1">12933525</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2006 Sep 2;368(9538):843-54</RefSource>
<PMID Version="1">16950362</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Intern Med. 2011 Jan 4;154(1):50-5</RefSource>
<PMID Version="1">21200038</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>BMJ. 2010;340:c365</RefSource>
<PMID Version="1">20156912</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2005 Sep 1;23(25):5910-7</RefSource>
<PMID Version="1">16087956</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst. 2003 Oct 1;95(19):1453-61</RefSource>
<PMID Version="1">14519751</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 1997 Dec 6;350(9092):1647-54</RefSource>
<PMID Version="1">9400508</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2002 Aug 17;360(9332):505-15</RefSource>
<PMID Version="1">12241653</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>BMC Pediatr. 2011;11:6</RefSource>
<PMID Version="1">21235822</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 1999 Mar 6;353(9155):793-6</RefSource>
<PMID Version="1">10459960</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Syst Rev. 2012;1:23</RefSource>
<PMID Version="1">22587912</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2008 May 1;358(18):1887-98</RefSource>
<PMID Version="1">18378519</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2006 Sep;7(9):719-27</RefSource>
<PMID Version="1">16945766</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 1995 Apr 15;345(8955):939-44</RefSource>
<PMID Version="1">7715291</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2013 Jun;14(7):619-26</RefSource>
<PMID Version="1">23680111</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2008 Dec 10;26(35):5802-12</RefSource>
<PMID Version="1">19001332</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>BMJ. 2006 Oct 14;333(7572):804-6</RefSource>
<PMID Version="1">17038740</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2013 Mar 9;381(9869):805-16</RefSource>
<PMID Version="1">23219286</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann N Y Acad Sci. 1993 Dec 31;703:156-63; discussion 163-5</RefSource>
<PMID Version="1">8192293</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2012 Oct;13(10):1045-54</RefSource>
<PMID Version="1">22954508</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2013 Mar 21;368(12):1101-10</RefSource>
<PMID Version="1">23514287</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2015 Jan;16(1):76-86</RefSource>
<PMID Version="1">25498218</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Cancer. 2007 Jan;43(1):114-21</RefSource>
<PMID Version="1">17084621</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2000 May 20;355(9217):1757-70</RefSource>
<PMID Version="1">10832826</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eval Health Prof. 2002 Mar;25(1):76-97</RefSource>
<PMID Version="1">11868447</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2001 Sep 29;358(9287):1033-41</RefSource>
<PMID Version="1">11589932</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>BMJ. 1995 Oct 7;311(7010):899-909</RefSource>
<PMID Version="1">7580546</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Diabet Med. 2005 Jul;22(7):882-8</RefSource>
<PMID Version="1">15975103</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2005 May 14-20;365(9472):1687-717</RefSource>
<PMID Version="1">15894097</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>BMJ. 1991 Oct 12;303(6807):884-93</RefSource>
<PMID Version="1">1834291</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J R Soc Med. 2007 Apr;100(4):187-90</RefSource>
<PMID Version="1">17404342</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2004 Jan 22;350(4):351-60</RefSource>
<PMID Version="1">14736927</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>JAMA. 2001 Jan 24-31;285(4):437-43</RefSource>
<PMID Version="1">11242428</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Stroke. 1997 Dec;28(12):2557-62</RefSource>
<PMID Version="1">9412649</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 1991 Sep;9(9):1668-74</RefSource>
<PMID Version="1">1831495</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur Urol. 2012 Dec;62(6):e99</RefSource>
<PMID Version="1">23018161</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015201" MajorTopicYN="Y">Meta-Analysis as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012107" MajorTopicYN="Y">Research Design</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D035842" MajorTopicYN="Y">Research Subjects</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013223" MajorTopicYN="Y">Statistics as Topic</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC4635379</OtherID>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Individual participant data (IPD)</Keyword>
<Keyword MajorTopicYN="N">Meta-analysis</Keyword>
<Keyword MajorTopicYN="N">Systematic review</Keyword>
<Keyword MajorTopicYN="N">Trial analysis</Keyword>
<Keyword MajorTopicYN="N">Trial conduct</Keyword>
<Keyword MajorTopicYN="N">Trial design</Keyword>
</KeywordList>
<InvestigatorList><Investigator ValidYN="Y"><LastName>Alderson</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Askie</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Bennett</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Burdett</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Clarke</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Dias</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Emberson</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Gueyffier</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Iorio</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Macleod</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Mol</LastName>
<ForeName>B W</ForeName>
<Initials>BW</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Moons</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Parmar</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Perera</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Phillips</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Pignon</LastName>
<ForeName>J P</ForeName>
<Initials>JP</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Rees</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Reitsma</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Riley</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Rovers</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Rydzewska</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Schmid</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Shepperd</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Stenning</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Stewart</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Tierney</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Tudur Smith</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Vale</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Welge</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>White</LastName>
<ForeName>I</ForeName>
<Initials>I</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Whiteley</LastName>
<ForeName>W</ForeName>
<Initials>W</Initials>
</Investigator>
</InvestigatorList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year>
<Month>10</Month>
<Day>10</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2015</Year>
<Month>04</Month>
<Day>15</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2015</Year>
<Month>05</Month>
<Day>27</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2015</Year>
<Month>7</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2015</Year>
<Month>7</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>2</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">26186982</ArticleId>
<ArticleId IdType="pii">S0895-4356(15)00268-1</ArticleId>
<ArticleId IdType="doi">10.1016/j.jclinepi.2015.05.024</ArticleId>
<ArticleId IdType="pmc">PMC4635379</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002741 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002741 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:26186982
   |texte=   How individual participant data meta-analyses have influenced trial design, conduct, and analysis.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:26186982" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a AustralieFrV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

How individual participant data meta-analyses have influenced trial design, conduct, and analysis.

How individual participant data meta-analyses have influenced trial design, conduct, and analysis.

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki